Stockscreener 앱 받기
9.11
1.19%
-0.10
전일 마감가:
$9.21
열려 있는:
$9.2
하루 거래량:
75,757
Relative Volume:
0.08
시가총액:
$636.37M
수익:
$202.09M
순이익/손실:
$-61.69M
주가수익비율:
-8.4352
EPS:
-1.08
순현금흐름:
$-35.64M
1주 성능:
-5.41%
1개월 성능:
-0.98%
6개월 성능:
-17.57%
1년 성능:
-17.87%
1일 변동 폭
$9.00
$9.20
1주일 범위
$9.00
$9.57
52주 변동 폭
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
EOLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.11 | 636.37M | 202.09M | -61.69M | -35.64M | -1.08 |
|
RGC
Regencell Bioscience Holdings Ltd
|
16.16 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
154.84 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.38 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.43 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.70 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | BTIG Research | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 - BioSpace
(EOLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Midday Stock Roundup: Xponential Fitness Down, Yoshiharu Up - Orange County Business Journal
Evolus Inc (EOLS) Stock Price Up 3.95% on Jun 11 - GuruFocus
Insider Spends US$189k Buying More Shares In Evolus - simplywall.st
Insider Buying: White Albert G III Acquires 20,000 Shares of Evolus Inc (EOLS) - GuruFocus
EOLS Director Boosts Stake with Significant Share Purchase | EOLS Stock News - GuruFocus
Evolysse™ Recognized in 2025 Shape Skin Awards | EOLS Stock News - GuruFocus
Evolysse™ Recognized in 2025 Shape Skin Awards - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Holdings Lowered by Squarepoint Ops LLC - Defense World
Evolus Announces Board Changes and Director Elections - TipRanks
Evolus, Inc. (EOLS) Stock Analysis: A 142% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Bank of America Corp DE - Defense World
EOLS Set to Participate in BTIG's Virtual Meeting on June 9 | EO - GuruFocus
Evolus, Inc. (NASDAQ:EOLS) Shares Bought by Ameriprise Financial Inc. - Defense World
EOLS Set to Participate in BTIG's Virtual Meeting on June 9 | EOLS Stock News - GuruFocus
Evolus Launches Second Product Line for Wrinkles - Orange County Business Journal
ProShare Advisors LLC Grows Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $347,000 Stock Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus announces CFO resignation - MSN
Stifel maintains Evolus stock buy rating, $25 target - Investing.com Australia
Stifel maintains Evolus stock buy rating, $25 target By Investing.com - Investing.com Nigeria
Increases to CEO Compensation Might Be Put On Hold For Now at Evolus, Inc. (NASDAQ:EOLS) - simplywall.st
Mizuho maintains Evolus stock Outperform rating and $25 target By Investing.com - Investing.com India
Evolus CFO Sandra Beaver resigns for new role By Investing.com - Investing.com South Africa
Mizuho maintains Evolus stock Outperform rating and $25 target - Investing.com
Evolus CFO to Resign - Orange County Business Journal
Evolus CFO Sandra Beaver Resigns - MarketScreener
Evolus (EOLS) CFO Resignation Announced - GuruFocus
Evolus CFO Sandra Beaver resigns for new role - Investing.com India
Evolus CFO Sandra Beaver Announces Resignation - TipRanks
Resignation of CFO Impacts Evolus (EOLS) Leadership | EOLS Stock News - GuruFocus
Evolus Announces Departure of its Chief Financial Officer | EOLS Stock News - GuruFocus
Evolus announces departure of CFO Sandra Beaver - TipRanks
Evolus Announces Departure Of Its Chief Financial Officer - marketscreener.com
Evolus Announces Departure of its Chief Financial Officer - Business Wire
BNP Paribas Financial Markets Has $400,000 Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolysse HA gels outperform Restylane in clinical study - Investing.com Australia
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels - marketscreener.com
Evolus announces publication of U.S. pivotal study for Evolysse injectable gels - TipRanks
EOLS Publishes Promising Study Results on Evolysse Injectable Gels | EOLS Stock News - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - BioSpace
Evolysse HA gels outperform Restylane in clinical study By Investing.com - Investing.com Canada
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels | EOLS Stock News - GuruFocus
Trend Tracker for (EOLS) - news.stocktradersdaily.com
Deutsche Bank AG Cuts Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Comerica Bank Purchases New Stake in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Evolus Inc 주식 (EOLS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks |
Jun 16 '25 |
Sale |
9.89 |
16,582 |
164,054 |
364,927 |
0.35%
0.00%
자본화:
|
볼륨(24시간):